Abstract: BACKGROUND: Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor prognosis in several malignancies. Here, we quantify the prognostic impact of this biomarker. METHODS: A systematic review of databases was conducted to identify publications exploring the association of blood PLR and overall survival (OS) in solid tumors. Data were pooled in a meta-analysis. Pooled HRs for OS by disease group and by PLR cutoff groups were computed and weighted using generic inverse-variance and randomeffect modeling. RESULTS: Twenty studies comprising 12,754 patients were assessed. Cutoffs for PLR defining risk groups ranged from 150 to 300 and were dichotomous (12 studies; group 1) or split into three groups (<150/150-300/>300, 8 studies; group 2). Higher PLR was associated with significantly worse OS in group 1 [HR = 1.87; 95% confidence interval (CI, 1.49-2.34); P < 0.001] and with a nonsignificant association in group 2 (HR per higher category = 1.21; 95%CI, 0.97-1.50; P = 0.10). The size of effect of PLR on OS was greater for metastatic disease (HR[group 1] = 2.0; 95% CI, 1.6-2.7; HR[group 2] = 1.6; 95% CI, 1.1-2.4) than for early-stage disease (HR[group 1] = 1.5; 95% CI, 1.0-2.2; HR[group 2] = 1.0; 95% CI, 0.8-1.3). A significant association was observed for colorectal, hepatocellular, gastroesophageal, ovarian, and pancreatic carcinoma in group 1 and for colorectal cancers in group 2. CONCLUSION: A high PLR is associated with worse OS in various solid tumors. Further research of its regulation and relevance in daily practice is warranted. IMPACT: PLR is a readily available and inexpensive biomarker with independent prognostic value in solid tumors. DOI: https://doi.org/10.1158/1055-9965. Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-104639 Accepted Version Originally published at: Templeton, Arnoud J; Ace, Olga; McNamara, Mairéad G; Al-Mubarak, Mustafa; Vera-Badillo, Francisco E; Hermanns, Thomas; Seruga, Boštjan; Ocaña, Alberto; Tannock, Ian F; Amir, Eitan (2014). Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiology Biomarkers Prevention, 23(7):1204-1212.
Introduction
Inflammation is a hallmark of cancer (1) and there is often a complex hosttumor relationship with most tumors having inflammatory cells and mediators present in their microenvironment (2, 3) . A variety of oncogenes, tumor secreted factors and cytokines secreted by inflammatory cells can lead to the recruitment of inflammatory mediators (3) . Based on these findings, a variety of markers of inflammation have been investigated for association with cancer progression and prognosis (4) .
White cell and neutrophil counts, elevated C-reactive protein (CRP) and hypoalbuminemia are the biochemical parameters associated with a systemic inflammatory response that are evaluated most often (4) . Several of these parameters have been converted to ratios or prognostic scores such as the Glasgow Prognostic Score (GPS, incorporating CRP and albumin) (5) or the neutrophil to lymphocyte ratio (NLR) (6) . Platelets are also part of the inflammatory response and thrombocytosis is common in patients with solid tumors (7, 8) . Platelets are known to interact with tumor cells directly and to contain factors that contribute to tumor growth, invasion and angiogenesis (9) . Platelets can protect tumor cells from NK-cell mediated lysis, thereby facilitating metastasis (10) . The link between thrombocytosis, poor prognosis and shorter survival time has been established in several types of solid tumors including breast, lung, colon, gastric, and ovarian cancer (11) . This is thought to occur due to thrombopoietic cytokines such as interleukin 6 (IL-6) being secreted by tumor cells (11) . With the recognition that low lymphocyte counts may also be associated with shorter survival (12) , the platelet to lymphocyte ratio (PLR) has been studied as a prognostic biomarker. It has been hypothesized that an increased PLR is indicative of an increased host inflammatory response associated with more aggressive tumor characteristics (13) .
The aim of the present study was to review the literature investigating the association of peripheral blood PLR in solid tumors with overall survival (OS) and to combine the results in a meta-analysis. Our hypothesis was that high PLR correlates with worse OS and may thus serve as a readily available and inexpensive prognostic marker in both clinical practice and for the stratification of patients in clinical trials.
Materials and Methods

This analysis was conducted in line with guidelines for the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (14) .
Data sources and searches
An electronic search of the following databases was undertaken: Medline Inclusion criteria were: (i) studies in solid tumors reporting the prognostic impact of the peripheral blood PLR, (ii) assessment of PLR by cut-off into different risk strata, and (iii) availability of a hazard ratio (HR) for OS or Kaplan Meier survival curves from which it could be calculated. Duplicate publications were excluded and for the main analysis so were studies that reported PLR as a continuous variable. Two reviewers (AT, MMN) evaluated independently all the titles identified by the search strategy. Inter-reviewer agreement was assessed using Cohen's kappa.
Disagreement was resolved by consensus. The results were then pooled and all potentially relevant publications retrieved in full and assessed for eligibility.
Corresponding authors were contacted to clarify any missing or ambiguous data.
Endpoints of interest
Survival based on high versus low PLR was the primary outcome of interest.
In exploratory analyses we compared the relative prognostic impact of PLR with other markers of inflammation, namely the neutrophil to lymphocyte ratio (NLR), Creactive protein (CRP), and the Glasgow Prognostic Score (GPS) or modified Glasgow Prognostic Score (mGPS).
Data extraction
Data were collected using predesigned abstraction forms. The following details were extracted: Name of first author, type of publication (abstract or full text), year of publication, journal, number of patients included in study, disease site, disease stage (non-metastatic, metastatic or mixed [i.e. non-metastatic and metastatic]), collection of data (prospective or retrospective), cut-off used to define high peripheral blood platelet to lymphocyte ratio (PLR), receiver operating characteristic (ROC) curves considered for selection of cut-off (yes or no), and HR for OS with associated Specifically, good quality studies were defined as those, which explicitly reported that patients with baseline infectious or inflammatory conditions were excluded form the analysis and where assessment of PLR was undertaken prior to treatment (surgery, systemic therapy or radiation). Extracted data were combined into a meta-analysis using RevMan 5.2 analysis software (Cochrane Collaboration, Copenhagen, Denmark). Estimates of HRs were weighted and pooled using the generic inverse variance and random-effect model. Analyses were conducted separately for studies using dichotomous groups and for three groups to define high versus low PLR.
Subgroup analyses were also conducted based on disease site and disease stage. the effect of study quality on the HR for OS. All statistical tests were two-sided, and statistical significance was defined as P< 0.05. No correction was made for multiple testing.
Results
Included studies
A total of 22 studies were identified ( Figure 1 ). Cohen's kappa for interreviewer agreement for paper selection was 0.78 (95% CI 0.63 -0.88). Studies included a total of 12,890 patients and characteristics of the studies are shown in Table 1 cut-off was 1.87 (95% CI 1.49 -2.34, P < 0.001, Figure 2A ). For studies of group 2 (i.e. two cut-offs defining low, intermediate and high PLR, usually <150, 150-300, >300) HR for OS per risk category was 1.21 (95% CI 0.97 -1.50, P = 0.10, Figure   2B ). There was statistically significant heterogeneity in both groups (group 1: Cochran Q P < 0.001, I 2 = 65%; group 2: Cochran Q P < 0.001, I 2 = 75%). In group 1, heterogeneity was introduced by one outlying study with HR = 4.81 (17) ; exclusion of this study reduced I 2 to 11% (P = 0.34) and changed the pooled estimate to 1.70 (95% CI 1.47 -1.95, P < 0.001). For group 2 no individual study could explain heterogeneity.
High PLR was associated with significantly worse survival for colorectal, gastro-esophageal, hepatocellular, pancreatic, and ovarian cancers in group 1 (HRs 1.57, 1.84, 3.33, 2.43, 1.57, respectively) but not for breast cancer ( Figure 3A ). For group 2, PLR was associated with worse survival only for colorectal cancer (HR 2.02)
but not for other disease sites ( Figure 3B ).
Overall, a prognostic role of PLR was observed for metastatic or mixed groups of patients (HR 2.03; 95% CI 1.55 -2.65, P = 0.001 and HR 1.61; 95% CI 1.10 -2.37, P = 0.01 for group 1 and group 2, respectively) but only for patients with nonmetastatic disease when a dichotomous cut-off was used (HR 1.48; 95% CI 1.01 -2.17, P = 0.04 and HR 1.04; 95% CI 0.82 -1.32, P = 0.73 for group 1 and group 2, respectively).
In sensitivity analyses, higher values of HR were reported in full papers as compared with abstracts in group 1, but not in group 2. Further subgroup comparisons and sensitivity analyses are shown in Table 2 . The scatter plot for the meta-regression is shown in Supplementary Figure 2 , available online. Overall, studies with good quality reported higher HR for OS than those for poor quality studies. This effect was 
and for those reporting 3 risk groups (β = 0.147, P = 0.001).
Comparison with Other Inflammatory Markers
The pooled HRs for PLR compared with other markers of inflammation, namely NLR, CRP, and GPS/mGPS were not statistically different (Table 3) . Only two studies reported HRs for NLR and PLR from multivariable analyses. In one of these studies (18) both NLR and PLR retained statistical significance. In the second study NLR was not independently prognostic after adjustment for PLR.
Discussion
Several studies have considered the relationship between inflammatory markers and outcome of patients with solid tumors. Here, we used meta-analysis to combine twenty studies exploring the prognostic role of PLR in 12,754 patients with solid tumors. Most of these studies have been published since 2012, highlighting the recent interest in PLR as a potential prognostic marker. We found an association between elevated PLR and poor survival. In studies reporting a dichotomous cut-off for PLR this association was seen among several disease sites and both for metastatic and non-metastatic disease whereas it was less apparent for studies reporting three risk categories defined by two different cut-offs for PLR. Presumably, this at least in part is due to numerically lower hazard ratios that apply per higher risk category compared to use of single cut-offs. As the direction of effect is the same, it may be hypothesized that if binary cut-offs had been used in studies reporting three risk groups, these may have reached statistically significance. Sensitivity analyses of type of publication and data collection did not change the overall result.
Differences in hazard ratios were observed between cancer sites and may be the result of inflammation playing differing roles in different types of cancer. For example, strong links with systemic inflammation and elevated inflammatory markers (CRP and GPS) have been established in colorectal cancer (4) . In the present analysis this is supported by a strong association between PLR and OS for this disease. In ovarian cancer, where we found a HR of 1.57, both thrombocytosis and elevated inflammatory markers have been linked to poor prognosis (4, 8) .
The mechanisms underlying the association of high PLR and poor outcome of cancer patients are poorly understood. Inflammatory cytokines and chemokines can be produced by both the tumor and associated host cells such as leukocytes and platelets, contributing to malignant progression (19) . Indeed, we found the strongest association between PLR and survival in metastatic or mixed groups of patients when compared to study populations with loco-regional disease. While a variety of cytokines are implicated in the systemic inflammatory response, IL-6 acts to increase the synthesis of acute phase proteins, including CRP, and to decrease albumin production in the liver, the two elements encompassed by the Glasgow Prognostic Score (20) . IL-6 also stimulates the differentiation of megakaryocytes to platelets and is involved in recruitment of neutrophils (21, 22) . Several studies have shown that IL-6 can stimulate thrombopoietin production and can lead to increases of platelet counts in cancer patients (23) . In patients with ovarian cancer, high IL-6 level is an independent predictor of poor prognosis (8) . Further, serum concentration of IL-6 has been shown to be increased in 13 different cancer types and has been associated with tumor stage and disease progression (22) . In an exploratory analysis we compared the relative prognostic impact of PLR with other markers of inflammation, namely NLR, CRP, and GPS/mGPS and did not find any of these to be a stronger prognostic marker then the others. In studies reporting HRs for both NLR and PLR, NLR was associated with a numerically higher HR for death in univariable analysis; this may be due to the more varied properties of neutrophils in comparison to platelets, such as the secretion of various cytokines (24) (25) (26) (27) , but this difference did not reach statistical significance. Either CRP or GPS/mGPS might be stronger predictors of survival than PLR but data from only 2 studies were available for comparison. Overall, it is likely that common mechanisms lead to concurrent elevation of multiple inflammatory factors.
Limitations of this study include the fact that only summarized data rather than individual patient data could be used and that two studies were published only in abstract form and have not undergone rigorous peer review. Second, most studies (70%) provided only HRs from univariable analysis which could introduce a bias towards overestimation of the prognostic role of PLR, as HRs in multivariable analysis may have been non-significant due to inclusion in the multivariable model of other markers of systemic inflammation such as CRP, hypoalbuminemia, GPS, or NLR. We aimed to address such confounding by performing sensitivity analyses and did not find a significant difference between subgroups. Furthermore, studies not reporting hazard ratios or Kaplan Meier curves were excluded, potentially introducing further bias. Finally, we cannot exclude the possibility that non-malignant factors may have influenced the reported PLR. Authors of most studies included in our analysis explicitly excluded patients with infection and/or inflammatory conditions and some mentioned exclusion of patients with hypothyroidism, hyperthyroidism, temperature >37.2C, or patients on glucocorticoids or non-steroidal anti-inflammatory drugs.
Furthermore, most studies reported that PLR was calculated from blood counts drawn 
prior to actual treatment. Our meta-regression suggests that the effect size of PLR on OS was greater in studies with more comprehensive exclusion of non-malignant causes of inflammation. Therefore, it is possible that our inclusion of studies without robust control for confounders actually diluted the effect of PLR on outcome.
To establish PLR as a prognostic marker, the clinical significance of this indicator must be further validated. The cut-off value must be established in one cohort of patients and tested in another and the number of patients in each group needs to be considered in the statistical analysis (28) . With the use of patient level data, the overlap of outcomes between high and low risk of PLR must be considered.
The differing results by cancer site and metastatic compared to locoregional disease reported here suggest that prognosis based on PLR may not be generalizable across differing patient groups.
In summary, this meta-analysis concludes that a high PLR is an independent factor associated with poorer overall survival in many solid tumors and is comparable to other established hematological markers of inflammation. As a cost-effective and readily available biomarker PLR may thus be useful in the clinical setting.
Investigation of the addition of PLR to established prognostic scores to stratify patients in clinical trials is warranted. The selection of the most relevant marker of inflammation to indicate prognosis will require head to head comparisons. CI, confidence interval; CRP, C-reactive protein; GPS, Glasgow Prognostic score; mGPS, modified GPS; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio. 
